Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14070624 | 1.00 | HSD17B10 (0.60) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL14070626 | 0.88 | STS (0.50) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL3430113 | 0.86 | CYP1A2 (0.80) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL14311225 | 0.86 | CYP1A2 (0.80) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL14070831 | 0.86 | HSD17B10 (0.60) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL14208960 | 0.85 | CYP19A1 (0.61) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL19922067 | 0.84 | STS (0.61) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL2758348 | 0.84 | CYP1A1 (0.60) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL2610030 | 0.84 | CA2 (0.60) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL14070775 | 0.84 | HSD17B10 (0.57) | HSD17B10LMNACYP1A2CYP3A4CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371741-B2 | Estradiol derivatives and pharmaceutical compositions using same | ENTREMED, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070135400-A1 | Estradiol derivatives | ENTREMED, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070010505-A1 | Methods of treating disease states using antiangiogenic agents | ENTREMED, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1633367-A2 | ANTIANGIOGENIC AGENTS | EntreMed, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005030120-A2 | ANTIANGIOGENIC AGENTS | ENTREMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050014737-A1 | Antiangiogenic agents | ENTREMED, INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135400-A1 | Estradiol derivatives | ESR2, NR5A1, ESRRB | HSD17B10 133/4885LMNA 3670/4885CYP1A2 218/4885 |
| US-20050014737-A1 | Antiangiogenic agents | VEGFA, TEK, FLT4 | HSD17B10 2784/4885LMNA 4052/4885CYP1A2 3144/4885 |
| US-20070010505-A1 | Methods of treating disease states using antiangiogenic agents | VEGFA, PGF, TEK | HSD17B10 1968/4885LMNA 2822/4885CYP1A2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.